Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
breast cancer primary prevention
mammographic breast density
mammographic breast density change
progesterone receptor
proliferation
tamoxifen
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
30 Mar 2024
30 Mar 2024
Historique:
revised:
25
02
2024
received:
20
11
2023
accepted:
29
02
2024
medline:
30
3
2024
pubmed:
30
3
2024
entrez:
30
3
2024
Statut:
aheadofprint
Résumé
Tamoxifen prevents recurrence of breast cancer and is also approved for preventive, risk-reducing, therapy. Tamoxifen alters the breast tissue composition and decreases the mammographic density. We aimed to test if baseline breast tissue composition influences tamoxifen-associated density change. This biopsy-based study included 83 participants randomised to 6 months daily intake of placebo, 20, 10, 5, 2.5, or 1 mg tamoxifen. The study is nested within the double-blinded tamoxifen dose-determination trial Karolinska Mammography Project for Risk Prediction of Breast Cancer Intervention (KARISMA) Study. Ultrasound-guided core-needle breast biopsies were collected at baseline before starting treatment. Biopsies were quantified for epithelial, stromal, and adipose distributions, and epithelial and stromal expression of proliferation marker Ki67, oestrogen receptor (ER) and progesterone receptor (PR). Mammographic density was measured using STRATUS. We found that greater mammographic density at baseline was positively associated with stromal area and inversely associated with adipose area and stromal expression of ER. Premenopausal women had greater mammographic density and epithelial tissue, and expressed more epithelial Ki67, PR, and stromal PR, compared to postmenopausal women. In women treated with tamoxifen (1-20 mg), greater density decrease was associated with higher baseline density, epithelial Ki67, and stromal PR. Women who responded to tamoxifen with a density decrease had on average 17% higher baseline density and a 2.2-fold higher PR expression compared to non-responders. Our results indicate that features in the normal breast tissue before tamoxifen exposure influences the tamoxifen-associated density decrease, and that the age-associated difference in density change may be related to age-dependant differences in expression of Ki67 and PR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Stockholm läns landsting
ID : 4-2645/2015
Organisme : Vetenskapsrådet
ID : E0718301
Organisme : Cancerfonden
ID : CAN 2015/649
Organisme : Cancerfonden
ID : CAN 21-0454 FE
Organisme : Cancerfonden
ID : CAN 21-1660
Organisme : Märit and Hans Rausing's Initiative Against Breast Cancer
Organisme : The Kamprad Foundation
ID : 20150052
Informations de copyright
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long‐term follow‐up of the IBIS‐I breast cancer prevention trial. Lancet Oncol. 2015;16:67‐75.
Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient‐level meta‐analysis of randomised trials. Lancet. 2011;378:771‐784.
Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134:875‐880.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P‐1 study. J Natl Cancer Inst. 2005;97:1652‐1662.
Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty‐year follow‐up of the Royal Marsden randomized, double‐blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283‐290.
He W, Grassmann F, Eriksson M, et al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J Clin Oncol. 2020;38:548‐557.
Dilli Batcha JS, Raju AP, Matcha S, et al. Factors influencing pharmacokinetics of tamoxifen in breast cancer patients: a systematic review of population pharmacokinetic models. Biology (Basel). 2022;12:51.
Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev. 2005;14:343‐349.
Ghosh K, Brandt KR, Reynolds C, et al. Tissue composition of mammographically dense and non‐dense breast tissue. Breast Cancer Res Treat. 2012;131:267‐275.
Gabrielson M, Chiesa F, Paulsson J, et al. Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues. Breast Cancer Res Treat. 2016;158:253‐261.
Gabrielson M, Hammarstrom M, Backlund M, et al. Effects of tamoxifen on normal breast tissue histological composition: results from a randomised six‐arm placebo‐controlled trial in healthy women. Int J Cancer. 2023;152:2362‐2372.
Decensi A, Robertson C, Viale G, et al. A randomized trial of low‐dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95:779‐790.
Eriksson M, Eklund M, Borgquist S, et al. Low‐dose tamoxifen for mammographic density reduction: a randomized controlled trial. J Clin Oncol. 2021;39:1899‐1908.
Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013;31:2249‐2256.
Cuzick J, Warwick J, Pinney E, et al. Tamoxifen‐induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011;103:744‐752.
Eriksson M, Li J, Leifland K, Czene K, Hall P. A comprehensive tool for measuring mammographic density changes over time. Breast Cancer Res Treat. 2018;169:371‐379.
Gabrielson M, Chiesa F, Behmer C, Ronnow K, Czene K, Hall P. Association of reproductive history with breast tissue characteristics and receptor status in the normal breast. Breast Cancer Res Treat. 2018;170:487‐497.
Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87:670‐675.
Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356:227‐236.
Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87:1622‐1629.
McCormack VA, dos Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta‐analysis. Cancer Epidemiol Biomark Prev. 2006;15:1159‐1169.
Dar H, Johansson A, Nordenskjold A, et al. Assessment of 25‐year survival of women with estrogen receptor‐positive/ERBB2‐negative breast cancer treated with and without tamoxifen therapy: a secondary analysis of data from the Stockholm Tamoxifen Randomized Clinical Trial. JAMA Netw Open. 2021;4:e2114904.
Colzani E, Liljegren A, Johansson AL, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29:4014‐4021.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869‐10874.
Abubakar M, Mullooly M, Nyante S, et al. Mammographic density decline, tamoxifen response, and prognosis by molecular characteristics of estrogen receptor‐positive breast cancer. JNCI Cancer Spectr. 2022;6:6.
Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54:R31‐R53.
Pang JM, Byrne DJ, Takano EA, et al. Breast tissue composition and immunophenotype and its relationship with mammographic density in women at high risk of breast cancer. PloS One. 2015;10:e0128861.
Battersby S, Robertson BJ, Anderson TJ, King RJ, McPherson K. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast. Br J Cancer. 1992;65:601‐607.
Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ. Mammographic densities and circulating hormones: a cross‐sectional study in premenopausal women. Breast. 2006;15:20‐28.
Iversen A, Frydenberg H, Furberg AS, et al. Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women. Eur J Cancer Prev. 2016;25:9‐18.
Gabrielson M, Azam S, Hardell E, et al. Hormonal determinants of mammographic density and density change. Breast Cancer Res. 2020;22:95.
Azam S, Sjolander A, Eriksson M, Gabrielson M, Czene K, Hall P. Determinants of mammographic density change. JNCI Cancer Spectr. 2019;3:pkz004.
Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95:30‐37.
Harvey J, Scheurer C, Kawakami FT, Quebe‐Fehling E, de Palacios PI, Ragavan VV. Hormone replacement therapy and breast density changes. Climacteric. 2005;8:185‐192.
Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001;285:171‐176.
Sartor H, Kontos D, Ullen S, Fornvik H, Fornvik D. Changes in breast density over serial mammograms: a case–control study. Eur J Radiol. 2020;127:108980.
Skarping I, Fornvik D, Heide‐Jorgensen U, et al. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast. 2020;53:33‐41.
Ko KL, Shin IS, You JY, Jung SY, Ro J, Lee ES. Adjuvant tamoxifen‐induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor‐positive premenopausal breast cancer patients. Breast Cancer Res Treat. 2013;142:559‐567.
Selli C, Dixon JM, Sims AH. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016;18:118.
Huo CW, Chew G, Hill P, et al. High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res. 2015;17:79.
Khan QJ, Kimler BF, O'Dea AP, Zalles CM, Sharma P, Fabian CJ. Mammographic density does not correlate with Ki‐67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer. Breast Cancer Res. 2007;9:R35.
Verheus M, Maskarinec G, Erber E, et al. Mammographic density and epithelial histopathologic markers. BMC Cancer. 2009;9:182.
Santandrea G, Bellarosa C, Gibertoni D, et al. Hormone receptor expression variations in normal breast tissue: preliminary results of a prospective observational study. J Pers Med. 2021;11:11.
Furberg AS, Jasienska G, Bjurstam N, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomark Prev. 2005;14:33‐40.
Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev. 2005;14:2641‐2647.
Abubakar M, Klein A, Fan S, et al. Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast. Breast Cancer Res. 2023;25:97.
Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC. Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol. 1995;142:813‐819.
Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst. 1992;84:1170‐1179.
Hawes D, Downey S, Pearce CL, et al. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res. 2006;8:R24.
Alowami S, Troup S, Al‐Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003;5:R129‐R135.
Lin SJ, Cawson J, Hill P, et al. Image‐guided sampling reveals increased stroma and lower glandular complexity in mammographically dense breast tissue. Breast Cancer Res Treat. 2011;128:505‐516.
Kelemen LE, Pankratz VS, Sellers TA, et al. Age‐specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol. 2008;167:1027‐1036.
Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomark Prev. 2006;15:732‐739.